CCB International: Maintaining Cinda Biotech's (01801) “Outperform the Market” rating and raising the target price to HK$54.7
Cinda Biotech (1801.HK): Strong revenue growth in the first quarter, various products will be unveiled at the ASCO conference
Cinda Biotech (01801.HK) In-depth Research Report: Excellent Operational Efficiency, Leading Indication Layout
Cinda Biotech (01801.HK) Annual Report Review Report: Revenue Growth and Loss Reduction Meet Expectations, Accelerated Delivery of Non-Oncology Pipelines
Cinda Biotech (1801.HK): Cardiovascular and metabolic products are expected to drive rapid growth in the company's performance
Bank Rating | CCB International: Raising Cinda Biotech's Target Price to HK$54.3 to Maintain “Outperform the Market” Rating
Southwest Securities: Cinda Biotech (01801) had a high increase in product revenue in 23, and the progress of many key products this year is worth looking forward to in ratings and maintaining purchases
Cinda Biotech (1801.HK): Revenue growth is in line with expectations, and operating efficiency continues to improve
CICC: Maintaining Cinda Biotech's (01801) “Outperform the Industry” Rating Target Price of HK$48
Cinda Biotech (01801.HK) 2023 Annual Report Review: Cinda Biotech's performance slightly exceeded expectations, chronic disease products entered the harvest period
Cinda Biotech (1801.HK): Performance is in line with expectations, high-potential pipelines provide growth impetus
Cinda Biotech (01801.HK): Various chronic disease products will be submitted to NDA for commercialization
INNOVENT BIOLOGICS(1801.HK):MORE THAN OBESITY
Bank Ratings | UBS: Raising Cinda Biotech's Target Price to HK$57.7 to Maintain “Buy” Rating
Cinda Biotech (1801.HK): Performance is in line with expectations, R&D and commercialization are worth looking forward to
Major Bank Rating | Goldman Sachs: Slightly Raising Cinda Biotech's Target Price to HK$61.29 Rating “Buy”
Cinda Biotech (01801.HK): Strong commercialization performance, innovation and implementation drive new growth
Cinda Biotech (1801.HK): Commercial products continue to be enriched and multiple catalysts are worth looking forward to
Macquarie: Maintaining Cinda Biotech's (01801) “Neutral” Rating and Raising the Target Price to HK$37
Nomura Adjusts Innovent Biologics' Price Target to HK$55.31 From HK$54.51, Keeps at Buy
No Data